Opportunities and Challenges in the Adult Attention-Deficit/Hyperactivity Disorder MarketDecision ResourcesNovember 14, 2005 25 Pages - SKU: DECR1188235 |
| Drug companies interested in entering the psychiatric market will find significant opportunity in the attention-deficit/hyperactivity disorder (ADHD) market, whose growth is being driven primarily by an increase in the diagnosed, drug-treated adult population. However, drug companies face a major challenge in this market: therapies with novel mechanisms of action are not needed because the currently marketed psychostimulants quickly and effectively alleviate ADHD symptoms. This report provides an overview of adult ADHD, including its prevalence in the major markets that we cover, discussion of current and emerging pharmacological therapies, the factors most likely to drive market growth over 2004-2014, and the challenges that face drug companies seeking to develop therapies for adult ADHD. Finally, we provide an outlook for the adult ADHD market, assessing the potential success of several emerging therapies. Please note: the PDF e-mail from publisher version of this report is for a global site license. |
Related Markets
Behavioral Health Reports
- Key Companies: Depression - Leading players must adapt to remain competitive
- CNS Market Access in China - Investment in mental health services offers growth opportunities for psychiatry players
- Product Profiles: Depression - Next generation vies for second-line patients
- Alcohol Addiction Global Clinical Trials Review, Q2, 2011
- Lifestyle Disorders Market to 2016 - Limited Pipeline Products and Slow Progress in R&D are Major Concerns
